AstraZeneca Settles Nexium Case With Ranbaxy; Can It Delay Other Generics?
Executive Summary
AstraZeneca expects its settlement agreement with Ranbaxy ending Nexium (esomeprazole) patent infringement litigation will win a nod of approval from the Federal Trade Commission
You may also be interested in...
Pay-For-Delay Antitrust Suits May Settle More Often After Jury Verdict For AstraZeneca
Jury finds AstraZeneca’s Nexium patent infringement settlement with Ranbaxy was not antitrust violation; direct purchasers and third party payers claimed agreement was worth nearly $1 billion.
Ranbaxy Exclusivity Implosion Pushes Valcyte Generics Towards Launch; Nexium Remains ‘Very Hazy’
FDA rescinds Ranbaxy’s esomeprazole and valganciclovir ANDA tentative approvals because of GMP compliance issues; firm loses its 180-day marketing exclusivity for valganciclovir but not for esomeprazole.
Ranbaxy Exclusivity Implosion Pushes Valcyte Generics Towards Launch; Nexium Remains ‘Very Hazy’
FDA rescinds Ranbaxy’s esomeprazole and valganciclovir ANDA tentative approvals because of GMP compliance issues; firm loses its 180-day marketing exclusivity for valganciclovir but not for esomeprazole.